Focus on SVR hinders Merck's Victrelis' German benefit review; may impact Janssen
This article was originally published in Scrip
Merck & Co's hepatitis C drug, Victrelis (boceprevir), appears to offer some additional benefit for patients who have not yet developed liver cirrhosis, but the extent of the benefit is uncertain, says IQWiG, Germany's Institute for Quality and Efficiency in Healthcare (IQWiG). Meanwhile, Janssen-Cilag, which markets competitor drug Incivo (telaprevir) is likely to be taking note, particularly given the institute's approach to sustained virological response (SVR) as an outcome. Work on an assessment of Incivo has already begun.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.